Figure 2.
FDG-PET scans of patient on the phase I trial of vemurafenib. Panels show scans of tumor burden at baseline and after 15 days of treatment at 960mg bid.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.